Pipeline

Fueled by a deep scientific expertise built over decades of research, Prothena is integrating scientific insights around protein dysregulation to advance a pipeline of therapeutic candidates for a number of neurodegenerative and rare peripheral amyloid diseases which affect millions of people and their families worldwide.

Program
Indication (Modality)

Protein Target

Discovery

Pre-clinical

Phase 1

Phase 2

Phase 3

Global Rights⁴

PrasinezumabParkinson’s disease
(mAb)

α-Synuclein
(C-terminus)

Phase 3 PARAISO trial ongoing

Coramitug (PRX004)ATTR amyloidosis
(mAb)

Transthyretin
(misTTR)

Phase 3 CLEOPATTRA trial ongoing

BMS-986446 (PRX005)Alzheimer’s disease
(mAb)

Tau (MTBR)

Phase 2 TargetTau-1 to complete in 1H 2027

PRX019Neurodegeneration
(mAb)

Undisclosed Target

Phase 1 to complete in 2026

TDP-43 CYTOPE^®ALS
(CYTOPE^®)

pTDP-43

PRX012-TfR³Alzheimer’s disease
(mAb)

Aβ (N-terminus)

mAb = monoclonal antibody; TfR = transferrin receptor
¹ Orphan Drug Designation granted by FDA & EMA; ² FDA Fast Track designation; ³ PRX012 has completed Phase 1b ASCENT program; PRX012 combination with transferrin receptor technology (PRX012-TfR) is in preclinical development; ⁴ In July 2021 Novo Nordisk acquired coramitug (formerly PRX004) and broader ATTR amyloidosis program and gained full worldwide rights. Prothena is eligible to receive up to $1.23 billion in total consideration.

Neurodegenerative

Rare Peripheral